Cargando…

Small-Molecule Inhibitor Targeting Protein Kinase D: A Potential Therapeutic Strategy

The protein kinase D (PKD) family is a family of serine-threonine kinases that are members of the calcium/calmodulin-dependent kinase (CaMK) superfamily. PKDs have been increasingly implicated in multiple pivotal cellular processes and pathological conditions. PKD dysregulation is associated with se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Die, Chen, Hongli, Feng, Yun, Cui, Bomiao, Kang, Yingzhu, Zhang, Ping, Luo, Min, Chen, Jiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263921/ https://www.ncbi.nlm.nih.gov/pubmed/34249722 http://dx.doi.org/10.3389/fonc.2021.680221

Ejemplares similares

Small molecule inhibitor CRT0066101 inhibits cytokine storm syndrome in a mouse model of lung injury
por: Cui, Bomiao, et al.
Publicado: (2023)

Protein kinase D3 regulates the expression of the immunosuppressive protein, PD-L1, through STAT1/STAT3 signaling
por: Cui, Bomiao, et al.
Publicado: (2020)

PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling
por: Cui, Bomiao, et al.
Publicado: (2021)

A Guide to Nucleic Acid Vaccines in the Prevention and Treatment of Infectious Diseases and Cancers: From Basic Principles to Current Applications
por: Qin, Furong, et al.
Publicado: (2021)

Small and Innovative Molecules as New Strategy to Revert MDR
por: Zinzi, Laura, et al.
Publicado: (2014)

Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development
por: Jin, Ye, et al.
Publicado: (2022)

Strategies for Discovery of Small Molecule Radiation Protectors and Radiation Mitigators
por: Greenberger, Joel S., et al.
Publicado: (2012)

Affinity probes based on small-molecule inhibitors for tumor imaging
por: Yi, Xinzeyu, et al.
Publicado: (2022)

The Atypical Protein Kinase C Small Molecule Inhibitor ζ-Stat, and Its Effects on Invasion Through Decreases in PKC-ζ Protein Expression
por: Smalley, Tracess, et al.
Publicado: (2020)

Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
por: Zhao, Qian, et al.
Publicado: (2022)

IDO Inhibitor and Gallic Acid Cross-Linked Small Molecule Drug Synergistic Treatment of Melanoma
por: Liu, Hongmei, et al.
Publicado: (2022)

Menin–MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers
por: Shi, Qing, et al.
Publicado: (2023)

Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
por: Zhao, Qian, et al.
Publicado: (2023)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
por: Hu, Chen-Yu, et al.
Publicado: (2019)

Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future
por: Huang, Wenda, et al.
Publicado: (2022)

Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
por: Pan, Jing-hua, et al.
Publicado: (2018)

Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer
por: Megino-Luque, Cristina, et al.
Publicado: (2020)

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
por: Wu, Donglu, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
por: Verougstraete, Nick, et al.
Publicado: (2022)

Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer
por: Duan, Yujuan, et al.
Publicado: (2022)

Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity
por: Gridnev, Artem, et al.
Publicado: (2022)

Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach
por: Zhang, He, et al.
Publicado: (2021)

Editorial: Unveiling the Impact of Local or Systemic Therapeutic Strategies on the Tumor Microenvironment
por: Chen, Yun-Wang, et al.
Publicado: (2022)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors
por: Xia, Qin, et al.
Publicado: (2020)

Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control
por: Pyo, Kyoung-Ho, et al.
Publicado: (2023)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
por: Cheng, Fang, et al.
Publicado: (2023)

A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer
por: Han, Shuai, et al.
Publicado: (2023)

Cuproplasia characterization in colon cancer assists to predict prognosis and immunotherapeutic response
por: Zhang, Bomiao, et al.
Publicado: (2023)

The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620
por: Zha, Jian-hua, et al.
Publicado: (2021)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Khaddour, Karam, et al.
Publicado: (2020)

The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
por: Kalra, Anjali, et al.
Publicado: (2023)

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
por: Mou, Lisha, et al.
Publicado: (2021)

Targeting the Tumor Extracellular Matrix by the Natural Molecule 4-Methylumbelliferone: A Complementary and Alternative Cancer Therapeutic Strategy
por: Vitale, Daiana L., et al.
Publicado: (2021)

Decoding kinase-adverse event associations for small molecule kinase inhibitors
por: Gong, Xiajing, et al.
Publicado: (2022)

First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations
por: Hu, Xiaolong, et al.
Publicado: (2022)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

An Update on Development of Small-Molecule Plasmodial Kinase Inhibitors
por: Moolman, Chantalle, et al.
Publicado: (2020)

Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
por: Viganò, Mauro, et al.
Publicado: (2023)

Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer
por: Niu, Huifeng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8cbd96td6varvtutc26r9upi7d